Management of endometriosis with oral medroxyprogesterone acetate.
Efficacy of oral medroxyprogesterone acetate (MPA) was assessed in 35 women with an established diagnosis of endometriosis (33 pelvic and 2 abdominal). MPA was given in a dosage of 30 mg daily for 90 days. Results indicated improvement or remission in all cases, even though breakthrough bleeding occurred in 8. Twenty-six were treated for associated infertility. Twelve of these became pregnant following treatment. Pregnancy rate in those women whose husbands were fertile was 90%. Side effects included spotting and breakthrough bleeding. The patients usually remained amenorrheic and anovulatory while receiving MPA. Posttreatment resumption of ovulation was prompt. The findings indicate that oral MPA is a useful therapeutic agent in the management of minimal to moderate endometriosis, particularly when it is associated with infertility.
D000008:Abdominal Neoplasms / Q000188:drug therapy*; D000284:Administration, Oral; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010386:Pelvic Neoplasms / Q000188:drug therapy*; D011247:Pregnancy; D011374:Progesterone / Q000097:blood
D011374:Progesterone; D008525:Medroxyprogesterone